Affimed Announces Addition to NASDAQ Biotechnology Index
December 17 2019 - 7:30AM
Heidelberg, Germany, December 17, 2019 – Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, today announced that it has been selected for addition to
the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition to the
NASDAQ Biotechnology Index will become effective prior to market
open on Monday, December 23, 2019.
The NASDAQ Biotechnology Index is designed to
track the performance of a set of securities listed on The Nasdaq
Stock Market® (NASDAQ®) that are classified as either biotechnology
or pharmaceutical according to the Industry Classification
Benchmark. The NASDAQ Biotechnology Index is re-ranked annually and
all securities in the index are listed on the NASDAQ Global Market
or the NASDAQ Global Select Market, and meet minimum market value
and share volume requirements among other criteria.
The NASDAQ Biotechnology Index is the basis for
the iShares NASDAQ Biotechnology exchange-traded fund (Nasdaq:
IBB). More information about the Index can be found at
https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage
biopharmaceutical company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat hematologic and solid tumors. For
more information, please visit www.affimed.com.
Affimed Investor and Media
Contact:
Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024